IDEAYA Biosciences Q1 2025 Update
Ticker: IDYA · Form: 10-Q · Filed: May 6, 2025 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, research-and-development, equity-incentive-plans
TL;DR
IDEAYA Bio Q1 2025 10-Q filed. Equity options exercised, research programs ongoing.
AI Summary
IDEAYA Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities, including details on its equity incentive plans and the exercise of outstanding options. The filing also references its cancer research technology agreements with Cancer Research Technology and The University of Manchester, and its Polymerase Theta program.
Why It Matters
This filing provides insight into IDEAYA's financial health and operational progress in its cancer research endeavors, which could impact its stock value and future development milestones.
Risk Assessment
Risk Level: medium — Biotech companies like IDEAYA Biosciences are inherently risky due to the long and uncertain development cycles of new drugs and therapies.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for this filing.)
- 20250506 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- Cancer Research Technology and The University of Manchester (company) — Parties to licensing agreements
- Polymerase Theta Program (program) — Key research initiative mentioned
FAQ
What were the key financial highlights for IDEAYA Biosciences in the quarter ending March 31, 2025?
The filing is a 10-Q which primarily details financial position and business activities, but specific financial highlights like revenue or net income are not detailed in the provided text snippet.
What is the status of IDEAYA's Polymerase Theta Program?
The Polymerase Theta Program is mentioned in the context of the company's research initiatives, with a reference to 'srt:MaximumMember' for the period ending March 31, 2025, suggesting ongoing development or evaluation.
Did IDEAYA Biosciences enter into any new licensing agreements during this period?
The filing references existing licensing agreements with 'idya:CancerResearchTechnologyAndTheUniversityOfManchesterMember' dating back to April 1, 2023, but does not explicitly state new agreements were entered into during the Q1 2025 period.
How many shares were issued or options exercised under IDEAYA's equity incentive plans?
The filing mentions 'idya:ExerciseOfOutstandingOptionsMember' for the period ending March 31, 2025, under various equity incentive plans, indicating option exercises occurred.
What is IDEAYA Biosciences' primary industry?
IDEAYA Biosciences, Inc. operates in the Pharmaceutical Preparations industry, with the Standard Industrial Classification code 2834.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding IDEAYA Biosciences, Inc. (IDYA).